InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.22
(
0.06%
)
US TECH 100
19,273.80
(
0.31%
)
Dow Jones
39,139.95
(
0.03%
)
Brent Oil
85.20
(
0.86%
)
Bitcoin
61,880.80
(
1.74%
)
Post# of 252398
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119931
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: frontiers post# 185195

Saturday, 12/27/2014 11:19:10 AM

Saturday, December 27, 2014 11:19:10 AM

Post# of 252398
ACHN—Your (latest) thesis is off-base, IMO. You’re now using a GILD trial of two nukes (one of which failed) to predict the trial outcome of ACHN’s combination of a nuke and an NS5A inhibitor!

Your prognostications of great success for ACHN have a familiar pattern: they are based on purported evidence of efficacy and safety derived from either your reading of patent filings or from another company’s clinical data. You previously described ACH-3422 as a turbocharged Sovaldi, which we now know isn't the case.

In truth, you won’t know whether ACHN has a competitive HCV regimen until ACHN completes combination studies of ACH-3102 + ACH-3422 (+ possibly Sovaprevir).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up